WallStreetZen

NYSE: ABBV
AbbVie Inc Stock Forecast, Predictions & Price Target

Analyst price target for ABBV

Based on 16 analysts offering 12 month price targets for AbbVie Inc.
Min Forecast
$96.00-13.14%
Avg Forecast
$114.38+3.49%
Max Forecast
$135.00+22.15%

Should I buy or sell ABBV stock?

Strong Buy
Strong Buy
12 analysts 66.67%
Buy
1 analysts 5.56%
Hold
5 analysts 27.78%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Forecast return on equity

Is ABBV forecast to generate an efficient return?
Company
140.19%
Industry
74.22%
Market
62.25%
ABBV's Return on Equity is forecast to be high in 4 years (140.19%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is ABBV forecast to generate an efficient return on assets?
Company
14.31%
Industry
16.87%
Market
19.66%
ABBV is forecast to generate lower Return on Assets (14.31%) than the US Drug Manufacturers - General industry average (16.87%)
Forecast

ABBV earnings per share forecast

What is ABBV's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$12.17+156.13%
Avg 2 year Forecast
$13.61+186.56%
Avg 3 year Forecast
$12.21+157.12%
ABBV's earnings are forecast to grow at an exceptional rate of 40.08% per year
Forecast

ABBV revenue forecast

What is ABBV's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$54.0B+32.96%
Avg 2 year Forecast
$57.9B+42.36%
Avg 3 year Forecast
$54.2B+33.41%
ABBV's revenue is forecast to grow at a rate of 11.33% per year, which is not exceptional
Forecast

ABBV earnings growth forecast

How is ABBV forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
40.08%
Industry
24.82%
Market
20.47%
ABBV's earnings are forecast to grow faster (40.08% per year) than the US Drug Manufacturers - General industry average (24.82%)
Forecast
ABBV's earnings are forecast to grow faster (40.08% per year) than the US market average (20.47%)
Forecast
ABBV's earnings are forecast to grow faster (40.08% per year) than the risk-free savings rate (1.1%)
Forecast

ABBV revenue growth forecast

How is ABBV forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
11.33%
Industry
6.43%
Market
14.48%
ABBV's revenues are forecast to grow faster (11.33% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
ABBV's revenues are forecast to grow slower (11.33% per year) than the US market average (14.48%)
Forecast

AbbVie Stock Forecast FAQ

Is AbbVie Stock a good buy in 2020, according to Wall Street analysts?

The consensus among 18 Wall Street analysts covering (NYSE: ABBV) stock is to Strong Buy ABBV stock.

Out of 18 analysts, 12 (66.67%) are recommending ABBV as a Strong Buy, 1 (5.56%) are recommending ABBV as a Buy, 5 (27.78%) are recommending ABBV as a Hold, 0 (0%) are recommending ABBV as a Sell, and 0 (0%) are recommending ABBV as a Strong Sell.

What is ABBV's Price Target?

According to 16 Wall Street analysts that have issued a 1 year ABBV price target, the average ABBV price target is $114.38, with the highest ABBV stock price forecast at $135.00 and the lowest ABBV stock price forecast at $96.00.

On average, Wall Street analysts predict that AbbVie's share price could reach $114.38 by Jan 15, 2022. The average AbbVie stock price prediction forecasts a potential upside of 3.49% from the current ABBV share price of $110.52.

What is ABBV's earnings growth forecast for 2021-2023?

(NYSE: ABBV) AbbVie's forecast annual earnings growth rate of 40.08% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 24.82%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 20.47%.

AbbVie's earnings in 2020 is $7,381,000,000.On average, 8 Wall Street analysts forecast ABBV's earnings for 2021 to be $21,471,490,721, with the lowest ABBV earnings forecast at $20,930,922,298, and the highest ABBV earnings forecast at $21,954,525,580. On average, 6 Wall Street analysts forecast ABBV's earnings for 2022 to be $24,022,380,695, with the lowest ABBV earnings forecast at $23,013,425,528, and the highest ABBV earnings forecast at $24,742,962,109.

In 2023, ABBV is forecast to generate $21,554,437,883 in earnings, with the lowest earnings forecast at $21,001,515,627 and the highest earnings forecast at $22,607,513,881.

What is ABBV's revenue growth forecast for 2021-2023?

(NYSE: ABBV) AbbVie's forecast annual revenue growth rate of 11.33% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.48%.

AbbVie's revenue in 2020 is $40,650,000,000.On average, 5 Wall Street analysts forecast ABBV's revenue for 2021 to be $95,388,908,687,316, with the lowest ABBV revenue forecast at $93,647,346,532,498, and the highest ABBV revenue forecast at $98,703,593,782,288. On average, 5 Wall Street analysts forecast ABBV's revenue for 2022 to be $102,127,183,207,204, with the lowest ABBV revenue forecast at $98,553,582,956,378, and the highest ABBV revenue forecast at $106,237,666,909,462.

In 2023, ABBV is forecast to generate $95,711,024,286,543 in revenue, with the lowest revenue forecast at $92,604,330,084,112 and the highest revenue forecast at $99,619,542,236,962.

What is ABBV's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: ABBV) AbbVie's current Earnings Per Share (EPS) is $4.75. On average, analysts forecast that ABBV's EPS will be $12.17 for 2021, with the lowest EPS forecast at $11.86, and the highest EPS forecast at $12.44. On average, analysts forecast that ABBV's EPS will be $13.61 for 2022, with the lowest EPS forecast at $13.04, and the highest EPS forecast at $14.02. In 2023, ABBV's EPS is forecast to hit $12.21 (min: $11.90, max: $12.81).

What is ABBV's forecast return on equity (ROE) for 2021-2024?

(NYSE: ABBV) forecast ROE is 140.19%, which is considered strong.

What is ABBV's forecast return on assets (ROA) for 2021-2024?

(NYSE: ABBV) forecast ROA is 14.31%, which is lower than the forecast US Drug Manufacturers - General industry average of 16.87%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics